ClinicalTrials.gg
CompletedNCT05805904Updated Sep 18, 2023

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants

A Phase 1 interventional study of BMS-986278 and Placebo in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in China. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-18.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the drug levels, safety, and tolerability of BMS-986278 in healthy Chinese participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be Chinese (both biological parents are ethnically Chinese).
  • Healthy Chinese male and female (women not of child bearing potential) participants as determined by no deviation from normal in medical history, physical examination, 12-lead ECGs, or clinical laboratory determinations.
  • of 18.0 to 28.0 kg/m2, inclusive. Body mass index = weight (kg)/(height [m])2.
  • Body weight ≥ 50 kg

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness that presents a potential risk to the participant and/or that may compromise the objectives of the study, including active, or history of, liver disease, or intestinal disorder including irritable bowel syndrome
  • Current or recent (within 3 months of study intervention administration) gastrointestinal (GI) disease that could affect the absorption, distribution, metabolism, and excretion of study drug (eg, bariatric procedure, Gilbert's syndrome)
  • Any GI surgery (eg, cholecystectomy and any other GI surgery) that, in the opinion of the investigator, could impact the absorption of study treatment (uncomplicated appendectomy and hernia repair are acceptable)
  • Women who are of
  • Women who are breastfeeding
  • Evidence of organ dysfunction or any deviation from normal in physical examination, vital signs, 12-lead , or clinical laboratory determinations beyond what is consistent with the target population. Have abnormal renal function at screening, as evidenced by an estimated \< 90 mL/min/1.732 m\^2 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula and the absence of protein in urine

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group 1

    Drug: BMS-986278 · Drug: Placebo

  • Experimental
    Group 2

    Drug: BMS-986278 · Drug: Placebo

Interventions

  • Specified dose on specified days.

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Up to Day 19

  2. Time of maximum observed concentration (Tmax)

    Time frame: Up to Day 19

  3. Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))

    Time frame: Up to Day 19

Secondary outcomes

  1. Number of participants with Adverse Events (AEs)

    Time frame: Up to Day 26

  2. Number of participants with physical examination abnormalities

    Time frame: Up to Day 19

  3. Number of participants with vital sign abnormalities

    Time frame: Up to Day 19

  4. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to Day 19

  5. Number of participants with clinical laboratory abnormalities

    Time frame: Up to Day 19

  6. Cmax

    Time frame: Up to Day 19

  7. Tmax

    Time frame: Up to Day 19

  8. AUC(0-T)

    Time frame: Up to Day 19

07

Study locations

1 site
  • Local Institution - 0001
    Shanghai, 200032, China
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in May 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2023
First posted
Apr 10, 2023
StartActual
Mar 29, 2023
Primary completionActual
May 23, 2023
CompletionActual
May 23, 2023
Last update
Sep 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05805904
Responsible party
Sponsor
First posted
Apr 10, 2023
Start date
Mar 29, 2023
Primary completion
May 23, 2023
Completion
May 23, 2023
Last update
Sep 18, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Admilparant

Start the discussion